Log In Get Started

Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

1,274 total articles

Churchill Downs Incorporated Statement Regarding United States District Court Victory in Churchill Downs Inc. v. Horseracing Integrity and Safety Authority
Mar 31, 2026
Priya Menon
Press Releases

Churchill Downs Incorporated Statement Regarding United States District Court Victory in Churchill Downs Inc. v. Horseracing Integrity and Safety Authority

Churchill Downs Incorporated announced a significant legal victory as the United States District Court ruled that the Horseracing Integrity and Safety Authority's fee methodology is arbitrary, capricious, and unlawful. This ruling challenges the authority's fiscal practices and may impact regulatory fee collections in the horse racing industry. Chu…

CHDN
Whitestone REIT Adds Premier Tenant at BLVD Place, Signs Agreement for Parkhill’s Houston Headquarters
Mar 31, 2026
Nina Shah
Press Releases

Whitestone REIT Adds Premier Tenant at BLVD Place, Signs Agreement for Parkhill’s Houston Headquarters

Whitestone REIT (NYSE: WSR) announced the signing of a 5,800-square-foot lease with architecture and engineering firm Parkhill at its premier BLVD Place mixed-use center in Houston's Uptown District. This lease underscores the strong demand for modern office space in a vibrant, amenity-rich environment. Whitestone's strategic repositioning of BLVD …

WSR
Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities
Mar 31, 2026
Nina Shah
Press Releases

Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities

Kala Bio Inc. has appointed Dr. Saeid Babaei as Senior Scientific Advisor to leverage AI and precision analytics in reassessing its clinical and molecular assets, particularly its proprietary MSC Secretome platform. This strategic move aims to unlock additional value by exploring amended indications and future development pathways including partner…

KALA
Westport Announces Issuance of Management Cease Trade Order
Mar 31, 2026
Ajmal Hussain
Press Releases

Westport Announces Issuance of Management Cease Trade Order

Westport Fuel Systems Inc. announced that the British Columbia Securities Commission has issued a temporary management cease trade order (MCTO) restricting trading by the CEO and CFO due to a cybersecurity incident which delayed the company's filing of its annual financial statements and related disclosures. The company is actively investigating th…

WPRT
JD.com Announces Pricing of CNY10 Billion CNY-denominated Senior Notes
Mar 31, 2026
Maya Rios
Press Releases

JD.com Announces Pricing of CNY10 Billion CNY-denominated Senior Notes

JD.com, a leading supply chain-based technology and service provider, announced the pricing of CNY10 billion aggregate principal amount of CNY-denominated senior unsecured notes via offshore transactions under Regulation S. The offering consists of CNY7.5 billion of 2.05% notes due 2031 and CNY2.5 billion of 2.75% notes due 2036. Proceeds will be u…

JD
Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease
Mar 31, 2026
Priya Menon
Press Releases

Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease

Ocugen, Inc. announced the early completion of dosing in its Phase 2/3 GARDian3 clinical trial for OCU410ST, a potential first-in-class modifier gene therapy for Stargardt disease. The trial enrolled 63 patients and aims to evaluate efficacy and safety in slowing the progression of this inherited retinal disorder. Interim data is expected in Q3 202…

OCGN
Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity
Mar 31, 2026
Priya Menon
Press Releases

Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity

Pasithea Therapeutics announced that the FDA has granted Fast Track designation to PAS-004, its next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (PN). This designation facilitates more frequent communication with the FDA, rolling review processes, and may enable accele…

KTTA
Apollomics Inc. Announces $2.0 Million Bridge Financing
Mar 31, 2026
Avery Klein
Press Releases

Apollomics Inc. Announces $2.0 Million Bridge Financing

Apollomics Inc., a clinical-stage biopharmaceutical company focused on oncology therapies, announced $2 million unsecured convertible promissory note financing from its CEO. The funds will support clinical development and corporate operations, with conversion linked to a future equity financing event. The financing terms were approved by the indepe…

APLM
NewGen Filed 2025 Annual Report on Form 20-F
Mar 31, 2026
Avery Klein
Press Releases

NewGen Filed 2025 Annual Report on Form 20-F

NewGenIVF Group Limited announced the filing of its 2025 annual report on Form 20-F with the SEC. The company operates a diversified business spanning real estate development in the UAE, digital asset and DeFi solutions, and reproductive health services in Asia. The report highlights strategic initiatives across these sectors and discloses associat…

NIVF
B2Gold Announces Renewal of Normal Course Issuer Bid
Mar 31, 2026
Leila Farooq
Press Releases

B2Gold Announces Renewal of Normal Course Issuer Bid

B2Gold Corp. has announced the renewal of its normal course issuer bid (NCIB), allowing the company to repurchase up to 132.7 million shares, equivalent to 10% of its public float, over the next 12 months. This move aligns with B2Gold's strategy to return value to shareholders and reflects management's belief that the shares may be undervalued. Sha…

BTO
Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions
Mar 31, 2026
Ajmal Hussain
Press Releases

Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions

Axsome Therapeutics has acquired exclusive global rights to balipodect (TAK-063), a selective PDE10A inhibitor from Takeda. The company plans to develop balipodect for schizophrenia and Tourette syndrome, initiating Phase 3 trial-enabling activities for schizophrenia in 2026. Balipodect represents a potential first-in-class mechanism targeting neur…

AXSM
Eldorado Gold Reminds Shareholders to Vote FOR the Share Issuance Resolution and Foran Mining Reminds Securityholders to Vote FOR the Arrangement Resolution
Mar 31, 2026
Derek Hwang
Press Releases

Eldorado Gold Reminds Shareholders to Vote FOR the Share Issuance Resolution and Foran Mining Reminds Securityholders to Vote FOR the Arrangement Resolution

Eldorado Gold Corporation and Foran Mining Corporation announced upcoming shareholder meetings for approval of a proposed plan of arrangement wherein Eldorado will acquire Foran, making it a wholly-owned subsidiary. The combined entity aims to leverage Eldorado's financial strength and operational platform with Foran's copper growth projects, targe…

ELD EGO FOM FMCXF
Lightbridge Receives Notice of Allowance on New U.S. Patent for its Metallic Fuel Assemblies for CANDU Reactors
Mar 31, 2026
Nina Shah
Press Releases

Lightbridge Receives Notice of Allowance on New U.S. Patent for its Metallic Fuel Assemblies for CANDU Reactors

Lightbridge Corporation announced receiving a Notice of Allowance from the USPTO for a new U.S. patent covering its advanced spirally twisted, multi-lobed metallic fuel assemblies designed for pressurized heavy-water reactors including CANDU-type designs. This strengthens their intellectual property portfolio for their advanced nuclear fuel technol…

LTBR
BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting
Mar 31, 2026
Maya Rios
Press Releases

BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting

BioXcel Therapeutics announced that the FDA has accepted its supplemental New Drug Application for IGALMI® to be used in the at-home setting to acutely treat agitation associated with bipolar disorders or schizophrenia. The FDA set a PDUFA action date of November 14, 2026. This approval could introduce the first FDA-approved at-home treatment for a…

BTAI
Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April
Mar 31, 2026
Maya Rios
Press Releases

Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April

Ocular Therapeutix, Inc. announced plans to present new data from their Phase 3 clinical trial of AXPAXLI (OTX-TKI) for wet age-related macular degeneration at upcoming scientific conferences in April 2026. The presentations aim to highlight the drug's efficacy and support its therapeutic potential, with sessions scheduled at the Vit-Buckle Society…

OCUL
FitLife Brands Announces Fourth Quarter and Full-Year 2025 Results
Mar 31, 2026
Jordan Park
Press Releases

FitLife Brands Announces Fourth Quarter and Full-Year 2025 Results

FitLife Brands announced its Q4 and full-year 2025 financial results highlighting a 73% increase in Q4 revenue and a 26% increase for the full year, largely fueled by the recent acquisition of Irwin Naturals. Despite growth in total and wholesale revenues, gross margins declined due to Irwin's historically lower margins and amortization expenses. N…

FTLF
Telix Appoints David Gill as Non-Executive Director
Mar 31, 2026
Ajmal Hussain
Press Releases

Telix Appoints David Gill as Non-Executive Director

Telix Pharmaceuticals Limited announced the appointment of David Gill as a Non-Executive Director effective May 11, 2026, with expectations that he will become Chair, succeeding Dr. Mark Nelson. Gill brings over 35 years of biotech and medical device leadership experience, including expertise in U.S. capital markets, positioning Telix for stronger …

TLX
Tilray Brands Delivers Record Q3 Fiscal 2026 Results; Net Revenue Increases to $207 Million with 11% Organic Growth and Gross Profit Expands to $55 Million, Increasing 6% Year-Over-Year
Mar 31, 2026
Sofia Navarro
Press Releases

Tilray Brands Delivers Record Q3 Fiscal 2026 Results; Net Revenue Increases to $207 Million with 11% Organic Growth and Gross Profit Expands to $55 Million, Increasing 6% Year-Over-Year

Tilray Brands, Inc. reported record third quarter fiscal 2026 results driven by 11% net revenue growth to $207 million and a 6% increase in gross profit to $55 million. The company exhibited strong international cannabis revenue growth of 73% year-over-year, solidifying its leadership in the Canadian cannabis market. The recent acquisition of BrewD…

TLRY
Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting
Mar 31, 2026
Leila Farooq
Press Releases

Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting

Rapport Therapeutics announced it will present new 8-week follow-up data from its Phase 2a trial of RAP-219, a novel targeted treatment for focal onset seizures, at the 2026 American Academy of Neurology Annual Meeting. RAP-219 specifically modulates the TARP-γ8 AMPA receptor subunit, potentially offering improved efficacy and tolerability for neur…

RAPP